Bipolar disorder treatment for Highland Beach — the diagnosis primary care misses.

RECO Integrated Psychiatry sits seven miles up A1A from Bel Lido Isle and Toscana — a 12-minute drive to a practice built around the medications bipolar disorder actually requires. Lithium is prescribed and monitored with the labs the drug demands, lamotrigine is titrated on the Stevens-Johnson protocol, and second-generation antipsychotics are matched to phase rather than defaulted. Diagnosis uses MDQ, HCL-32, and structured mood charting to catch the bipolar depression that general practices routinely miss as unipolar.

Highland Beach is the narrow oceanfront strip between Delray and Boca Raton, and for residents of Bel Lido Isle, Toscana, Boca Cove, Ocean Cove, and Penthouse, the drive up A1A to RECO Integrated Psychiatry’s Delray Beach campus runs roughly seven miles and twelve minutes. That proximity matters because bipolar illness is one of the diagnoses most often missed in general behavioral-health settings, and specialist-level bipolar disorder treatment is not something a primary-care practice or a general therapy office is structured to deliver.

Bipolar I, bipolar II, and bipolar spectrum: getting the diagnosis right

The single most consequential decision in bipolar care is the diagnosis itself. Bipolar I requires a full manic episode — at least seven days of elevated or irritable mood with functional impairment, hospitalization, or psychotic features. Bipolar II requires a hypomanic episode plus at least one major depressive episode; hypomania is briefer, less disabling, and routinely unrecognized by the patient. Bipolar spectrum presentations — cyclothymia, BP-NOS, subthreshold hypomania, antidepressant-emergent hypomania — cover people with clear cyclical mood pathology who do not meet full DSM-5 criteria.

The distinction dictates the pharmacology. Bipolar I responds to lithium or valproate combined with a second-generation antipsychotic during acute mania and often through maintenance. Bipolar II depression responds strongly to lamotrigine and quetiapine but not reliably to lithium monotherapy. Bipolar spectrum presentations require the most cautious antidepressant use, always under mood stabilizer cover, because unopposed SSRIs and SNRIs can accelerate cycling or trigger hypomanic switching.

RECO’s diagnostic workup uses the Mood Disorder Questionnaire (MDQ), the Hypomania Checklist (HCL-32), retrospective mood charting, structured hypomania interview, and collateral history from a partner or family member where available. Misdiagnosis of bipolar depression as unipolar depression is the single largest driver of treatment failure in this population, and the workup is built to catch it before an antidepressant destabilizes the course of illness.

Lithium: the treatment RECO takes seriously

Lithium remains the most effective long-term mood stabilizer in bipolar disorder and the only psychotropic medication with robust randomized-trial evidence for reducing suicide. Its underuse in community psychiatry is driven not by efficacy data but by the monitoring burden — baseline TSH, creatinine, calcium, and CBC, plus an EKG in patients over fifty or with cardiac history, and pregnancy testing where relevant.

Maintenance serum levels target 0.6 to 1.0 mEq/L, drawn twelve hours post-dose, with quarterly monitoring in the first year and semiannual monitoring thereafter. Weight, thyroid function, and renal function are tracked at each interval. ACE inhibitors, NSAIDs, and thiazide diuretics can raise lithium levels significantly and require dose adjustment; patients are counseled on hydration and on which over-the-counter medications to avoid.

Lithium is not universally tolerable — tremor, polyuria, cognitive dulling, and weight gain lead some patients to discontinue. But when it works, the reduction in episode frequency, hospitalization, and suicide risk justifies the labs. RECO’s protocol builds monitoring into the visit cadence rather than treating it as an obstacle, which is why lithium is prescribed here more often than in most general psychiatric practices.

Second-generation antipsychotics: matching the agent to the phase

Second-generation antipsychotics carry FDA approval for specific phases of bipolar illness, and the selection is driven by which phase is being treated. Quetiapine has approval across acute mania, bipolar depression, and maintenance, which makes it one of the most versatile agents. Lurasidone and cariprazine are approved for bipolar depression with more favorable metabolic profiles than quetiapine or olanzapine. Aripiprazole is indicated for acute mania and maintenance but carries limited efficacy in bipolar depression. Olanzapine — alone or as the olanzapine-fluoxetine combination — is effective across mania and bipolar depression but carries the heaviest metabolic burden.

Metabolic monitoring is standard: weight and BMI at each visit, fasting glucose or HbA1c and a lipid panel at baseline, three months, and annually. Blood pressure is checked at every visit. For patients with baseline metabolic syndrome, elevated HbA1c, or a family history of type 2 diabetes, lurasidone or cariprazine is typically prioritized over quetiapine or olanzapine.

Prior response and prior tolerability weigh heavily in the choice. RECO’s prescribing does not default to a single agent; the selection is phase-specific, side-effect-specific, and adjusted iteratively as clinical data accumulates over the first six to twelve weeks.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine has the strongest evidence for maintenance treatment of bipolar disorder when depression is the predominant pole, and it is a first-line option in bipolar II. Titration is deliberately slow — 25 mg daily for two weeks, 50 mg for two weeks, 100 mg for one week, then 200 mg — to reduce the risk of Stevens-Johnson syndrome. Any rash during titration triggers immediate discontinuation and clinical evaluation. Lamotrigine does not treat acute mania and is not a stand-alone option in mania-predominant illness.

Valproate (divalproex) is effective for acute mania, mixed episodes, and maintenance, particularly in patients with rapid cycling. Monitoring includes baseline and periodic LFTs, CBC with platelets, and serum levels in the 50-125 mcg/mL range. Valproate is teratogenic and is avoided in patients of reproductive potential unless clinical need is compelling and contraception is reliable and documented.

Carbamazepine and oxcarbazepine are second-line anticonvulsant options useful in patients who have not responded to lithium or valproate; each carries its own drug-interaction and monitoring profile. RECO’s practice runs all of the standard anticonvulsant protocols rather than defaulting to a single agent, which matters when a patient has already cycled through the obvious choices.

What to expect on your first visit

The initial evaluation at RECO runs 60 to 90 minutes with a board-certified psychiatrist or psychiatric nurse practitioner. History covers mood episode chronology, prior medication trials with dose and duration, family psychiatric history, sleep architecture, substance use, and functional trajectory. Structured screening tools — MDQ, HCL-32, PHQ-9, GAD-7, and where indicated the ASRS for adult ADHD — anchor the workup.

Baseline labs are ordered the same day when clinically relevant: TSH, CBC, comprehensive metabolic panel, HbA1c, lipid panel, and serum lithium or valproate level for patients already on those medications. Diagnostic impressions and initial treatment recommendations are discussed at the end of the first visit; follow-up is typically two to four weeks out for adjustments and then spaced to monthly and quarterly as stability is established. For Highland Beach residents, most follow-up visits can be completed by secure telepsychiatry once the diagnostic workup and initial titration are complete.

Insurance and admissions from Highland Beach

RECO Integrated Psychiatry is in network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield, and staff verify benefits prior to the initial visit. Specialist copays, deductible status, and prior authorization requirements for TMS or Spravato are confirmed in writing before treatment begins.

Same-week new-patient evaluations are typically available for Highland Beach residents, and the twelve-minute drive from Bel Lido Isle, Toscana, Boca Cove, Ocean Cove, or Penthouse up A1A to the Delray Beach campus keeps continuity of care realistic long-term.

Serving residents of: Bel Lido Isle, Boca Cove, Ocean Cove, Toscana, Penthouse.